For the most recent Top Companies List, click here.

There are no new names in our Top 20 Pharma ranks, but mega-mergers and patent expirations have re-shaped the upper end the list this year. Pfizer stayed on top for another year (although it may choose to abdicate), but Novartis creeped up from #3 to #2, boosted by its Alcon revenues, and Merck jumped from #6 to #3 after integrating Schering-Plough’s sales. Sanofi and GlaxoSmithKline, meanwhile, both fell behind as their annual sales dropped from 2009. (Good thing Sanofi will be able to add in some Genzyme revenues next year!)
 

Pharma is in the midst of some tumultuous times. I foresee a lot more jockeying for position in the next several years.
 

—Gil Y. Roth

Editor

Contributors

Editor: Gil Y. Roth

Associate Editor: Kristin Brooks

Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks

The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)

Pipeline information compiled by Kristin Brooks

Revenue information compiled by Gil Roth

Top 20 Pharma Companies